Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP).
The contract covers a full technology transfer for the vaccine manufacturing process from Nordic Bavaria to SII, with the aim of increasing production capacity and future supply for low- and middle-income endemic countries.
The new agreement builds on the existing license and manufacturing partnership between the two companies for the mpox vaccine.
It replaces a previous agreement with Biological E. Both parties will also explore potential co-development opportunities as part of this expanded collaboration.
Bavarian Nordic President and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India.
“By leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the world.”
The CHIKV VLP vaccine is a preloaded, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunization against chikungunya virus disease in persons 12 years of age and older.
It is designed to trigger a strong serological response, with protective immunity beginning to develop as early as a week after vaccination.
Because it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad demographic population.
Marketed as Vimkunya, CHIKV VLP received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission and the US Food and Drug Administration (FDA) in 2025.
A regulatory review is underway in Canada and Switzerland.
In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK.
The launch followed a significant increase in cases of travel-related illnesses reported across the country. The UK Health Security Agency (UKHSA) stated that the incidence increased by 170% in August 2025 compared to the same period in 2024.
“Bavarian Nordic and SII sign agreement for the production of chikungunya vaccines” was originally created and published by Pharmaceutical Technology, a brand owned by GlobalData.
The information contained on this site has been included in good faith for general information purposes only. It is not intended to be advice on which you should rely, and we make no representation or warranty, whether express or implied, as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action based on the content on our site.